Aduro Biotech, Inc. (ADRO) Files Form 4 Insider Selling : Jennifer Lew Sells 6,360 Shares

Aduro Biotech, Inc. (ADRO): Jennifer Lew , Sr. Vice President of Finance of Aduro Biotech, Inc. sold 6,360 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $14.95 per share for a total value of $95,082.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 2, 2016, Thomas W. Dubensky (Chief Scientific Officer) sold 25,000 shares at $14.03 per share price.On May 18, 2016, Dirk G. Brockstedt (Sr. VP of Research and Dev.) sold 905 shares at $8.20 per share price.Also, On May 18, 2016, Gregory W Schafer (Chief Operating Officer) sold 905 shares at $8.20 per share price.On Jan 6, 2016, Stephen T Isaacs (President and CEO) sold 25,000 shares at $26.63 per share price.

Aduro BioTech Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Aduro BioTech Inc which led to swings in the share price. The shares opened for trading at $14.7 and hit $14.76 on the upside , eventually ending the session at $14.535, with a gain of 0.45% or 0.065 points. The heightened volatility saw the trading volume jump to 3,53,468 shares. The 52-week high of the share price is $34.95 and the company has a market cap of $941 M . The 52-week low of the share price is at $7.26.

Aduro BioTech Inc Money Flow Index Chart

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live attenuated Listeria GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207 ADU-623 ADU-214 ADU-741 CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.

Leave a Reply

Aduro BioTech Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aduro BioTech Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.